Celltrion pulls off $300m convertible bond without any hedging chances
South Korean biopharmaceutical company Celltrion closed a $300m convertible bond this week, managing to bring in hedge funds to take around $75m of the deal despite not offering any stock borrow.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts